Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, Piper Sandler Analyst Says

Scholar Rock (NASDAQ:SRRK) had its price objective raised by analysts at Piper Sandler from $51.00 to $58.00 in a report issued on Wednesday, MarketBeat reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target indicates a potential upside of 25.68% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Citigroup began coverage on shares of Scholar Rock in a report on Friday, January 9th. They set a “buy” rating and a $55.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday. Wolfe Research started coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price on the stock. Finally, Barclays lifted their price target on shares of Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday. Four research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $54.14.

Scholar Rock Price Performance

Scholar Rock stock opened at $46.15 on Wednesday. The stock has a market cap of $5.30 billion, a P/E ratio of -13.45 and a beta of 0.70. The company has a fifty day simple moving average of $45.33 and a 200-day simple moving average of $39.19. The company has a current ratio of 6.95, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock has a 12-month low of $22.71 and a 12-month high of $49.82.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period last year, the firm earned ($0.64) earnings per share. Equities analysts expect that Scholar Rock will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Scholar Rock

In related news, insider Jing L. Marantz sold 4,157 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider owned 126,012 shares of the company’s stock, valued at $5,863,338.36. This trade represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Junlin Ho sold 9,580 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $445,757.40. Following the completion of the transaction, the general counsel owned 241,545 shares in the company, valued at $11,239,088.85. This trade represents a 3.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 208,470 shares of company stock worth $9,201,778 in the last quarter. 13.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. IFP Advisors Inc increased its holdings in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Scholar Rock in the 4th quarter valued at $30,000. Summit Securities Group LLC acquired a new position in Scholar Rock in the 4th quarter valued at $31,000. EverSource Wealth Advisors LLC increased its stake in Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares during the period. Finally, Hilton Head Capital Partners LLC purchased a new position in Scholar Rock during the 4th quarter worth $44,000. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Major analysts raised ratings and targets — BMO bumped its target to $70 (Outperform), Citigroup raised its target to $58 (Buy) and Piper Sandler lifted its target to $58 (Overweight), signaling fresh upside expectations. Analyst Price Target Raises Piper Sandler Note
• Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $1.26 (from $1.07) and reiterated a Buy rating with a $58 price target — a bullish long‑term earnings view that contrasts with current street estimates. HC Wainwright Upgrade
• Positive Sentiment: Scholar Rock reported progress on apitegromab: management outlined a 2026 BLA resubmission plan and commercial launch preparations following favorable interactions with the FDA — this is the primary operational catalyst for upside if approval and launch proceed. FDA / BLA Progress
• Neutral Sentiment: Q4 2025 results marginally beat expectations (EPS about -$0.88 vs. consensus ~ -$0.8825), showing stability but not a strong inflection in near‑term profitability. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Street consensus still expects a negative EPS for the current fiscal year (≈ -$2.42), underlining that near‑term earnings and cash‑flow risk remain until apitegromab is approved and commercialized. Consensus EPS Context

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).